{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:51:18Z","timestamp":1788371478249,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2023\\u201300277551"],"award-info":[{"award-number":["RS-2023\\u201300277551"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118722","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T02:22:06Z","timestamp":1761790926000},"page":"118722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Physiologically-based pharmacokinetic modeling of enavogliflozin ophthalmic solution for starting dose selection in diabetic retinopathy treatment"],"prefix":"10.1016","volume":"193","author":[{"given":"Dong Wook","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0784-3381","authenticated-orcid":false,"given":"Seok-jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go-Wun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5995-6547","authenticated-orcid":false,"given":"Hea-Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118722_bib1","article-title":"Diabetic retinopathy and diabetic macular edema","volume":"55","author":"Cohen","year":"2015","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118722_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s40123-017-0083-9","article-title":"A review of ranibizumab for the treatment of diabetic retinopathy","volume":"6","author":"Stewart","year":"2017","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.biopha.2025.118722_bib3","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v4.i6.303","article-title":"Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema","volume":"4","author":"Moradi","year":"2013","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.biopha.2025.118722_bib4","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2025.118722_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118722_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010111","article-title":"Ocular and plasma pharmacokinetics of enavogliflozin ophthalmic solution in preclinical species","volume":"17","author":"Jang","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118722_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s40005-023-00653-8","article-title":"Multicompartmental pharmacokinetic evaluation of enavogliflozin eye drop formulation: understanding its distribution to posterior segments","volume":"54","author":"Cho","year":"2024","journal-title":"J. Pharm. Invest."},{"key":"10.1016\/j.biopha.2025.118722_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9254126","article-title":"Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy","volume":"2018","author":"Herat","year":"2018","journal-title":"Int J. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118722_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2017.06.012","article-title":"Comparison of the expression and spatial localization of glucose transporters in the rat, bovine and human lens","volume":"161","author":"Lim","year":"2017","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11206183","article-title":"Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?","volume":"11","author":"Wo\u0142os-K\u0142osowicz","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2025.118722_bib11","unstructured":"Daewoong Therapeutics, Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World\u2019s First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema, 2023.."},{"key":"10.1016\/j.biopha.2025.118722_bib12","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1111\/dom.15738","article-title":"Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: a 52-week extension of a Phase 3 randomized controlled trial","volume":"26","author":"Kwak","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118722_bib13","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1111\/dom.15573","article-title":"The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes","volume":"26","author":"Jeong","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118722_bib14","article-title":"Physiologically-based pharmacokinetic model for evaluating gender-specific exposures of N-nitrosodimethylamine (NDMA)","volume":"98","author":"Kang","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2025.118722_bib15","series-title":"Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation","author":"EMA","year":"2018"},{"key":"10.1016\/j.biopha.2025.118722_bib16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK modeling and simulation in drug research and development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118722_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/jvp.12861","article-title":"Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part I: cattle and swine","volume":"43","author":"Lin","year":"2020","journal-title":"J. Vet. Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118722_bib18","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00204-024-03828-w","article-title":"PBPK model-based gender-specific risk assessment of N-nitrosodimethylamine (NDMA) using human biomonitoring data","volume":"98","author":"Kang","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2025.118722_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jat.1225","article-title":"Evaluation of physiologically based pharmacokinetic models for use in risk assessment","volume":"27","author":"Chiu","year":"2007","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.biopha.2025.118722_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10837450902891360","article-title":"Physiologically based pharmacokinetics (PBPK)","volume":"41","author":"Espi\u00e9","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biopha.2025.118722_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030838","article-title":"Application of minimal physiologically-based pharmacokinetic model to simulate lung and trachea exposure of pyronaridine and artesunate in hamsters","volume":"15","author":"Kang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK modeling: how to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00997","article-title":"Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges","volume":"11","author":"Zou","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867457","article-title":"PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer\u2019s disease","volume":"13","author":"Bloomingdale","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103731","article-title":"3D printing combined with biopredictive dissolution and PBPK\/PD modeling optimization and personalization of pharmacotherapy: Are we there yet?","volume":"28","author":"Wyszogrodzka-Gawe\u0142","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118722_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2023.2283524","article-title":"Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK\/PD modelling","volume":"19","author":"Gao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2025.118722_bib27","article-title":"Approaches for estimating the clinical starting dose of new dosage forms: an example of a long-acting injectable formulation of finasteride","volume":"631","author":"Kang","year":"2023","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2021.10.022","article-title":"Long-acting injectable donepezil microspheres: formulation development and evaluation","volume":"340","author":"Choi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118722_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s40005-022-00562-2","article-title":"Population pharmacokinetic modeling and simulation of choline in healthy Korean subjects after oral administration of choline alfoscerate","volume":"52","author":"Im","year":"2022","journal-title":"J. Pharm. Invest."},{"key":"10.1016\/j.biopha.2025.118722_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120527","article-title":"Pharmacokinetic-pharmacodynamic modeling approach for dose prediction of the optimal long-acting injectable formulation of finasteride","volume":"601","author":"Kang","year":"2021","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib31","doi-asserted-by":"crossref","DOI":"10.12793\/tcp.2015.23.2.38","article-title":"Physiological spaces and multicompartmental pharmacokinetic models","volume":"23","author":"Atkinson","year":"2015","journal-title":"Transl. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib32","author":"Padda","year":"2022","journal-title":"SodiumGlucose Transp. Protein 2 (SGLT2) Inhib."},{"key":"10.1016\/j.biopha.2025.118722_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15348","article-title":"Dose-dependent glucosuria of DWP16001, a novel selective sodium\u2013glucose cotransporter-2 inhibitor, in healthy subjects","volume":"88","author":"Hwang","year":"2022","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib34","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-011-9297-2","article-title":"Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: Implications for quantitative translational pharmacology","volume":"13","author":"Maurer","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2025.118722_bib35","article-title":"The arrive guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.biopha.2025.118722_bib36","unstructured":"US EPA, Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment, 2006. \u3008https:\/\/ordspub.epa.gov\/ords\/eims\/eimscomm.getfile?p_download_id=458188\u3009."},{"key":"10.1016\/j.biopha.2025.118722_bib37","doi-asserted-by":"crossref","unstructured":"R.P. Brown, M.D. Delp, S.L. Lindstedt,; Lorenz, R. Rhomberg, R.P. Beliles, Physiological parameter values for physiologically based pharmacokinetic models, 1997.","DOI":"10.1177\/074823379701300401"},{"key":"10.1016\/j.biopha.2025.118722_bib38","article-title":"Revisiting a physiologically based pharmacokinetic model for cocaine with a forensic scope","volume":"8","author":"Bravo-G\u00f3mez","year":"2019","journal-title":"Toxicol. Res (Camb. )"},{"key":"10.1016\/j.biopha.2025.118722_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2006.09.005","article-title":"Microspheres method for ocular blood flow measurement in rats: Size and dose optimization","volume":"84","author":"Wang","year":"2007","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib40","first-page":"501","author":"Kenyon","year":"2012","journal-title":"Inter. Extra"},{"key":"10.1016\/j.biopha.2025.118722_bib41","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.3390\/ijms25136998","article-title":"Inter-species pharmacokinetic modeling and scaling for drug repurposing of pyronaridine and artesunate","volume":"25","author":"Kang","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118722_bib42","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/15287390601172056","article-title":"Postnatal growth considerations for PBPK modeling","volume":"70","author":"Luecke","year":"2007","journal-title":"Journal Toxicology Environmental Health Part A Current Issues"},{"key":"10.1016\/j.biopha.2025.118722_bib43","article-title":"Physiologically based pharmacokinetic modelling to predict pharmacokinetics of enavogliflozin, a sodium-dependent glucose transporter 2 inhibitor, in humans","volume":"15","author":"Kim","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib44","article-title":"Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies","author":"Naware","year":"2023","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib45","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.8b00280","article-title":"Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic\/pharmacodynamic model","volume":"15","author":"Hutton-Smith","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennern\u00e4s","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2025.118722_bib47","doi-asserted-by":"crossref","DOI":"10.1023\/A:1020483911355","article-title":"Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs","volume":"19","author":"Sun","year":"2002","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2025.118722_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/15287394.2012.722523","article-title":"Development of pbpk models for pfoa and pfos for human pregnancy and lactation life stages","volume":"76","author":"Loccisano","year":"2013","journal-title":"J. Toxicol. Environ. Hlth. Part A Curr. Issues"},{"issue":"1-3","key":"10.1016\/j.biopha.2025.118722_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0300-483X(96)03383-5","article-title":"Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform","volume":"111","author":"Allen","year":"1996","journal-title":"Toxicology"},{"key":"10.1016\/j.biopha.2025.118722_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030268","article-title":"Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin","volume":"12","author":"Choi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061210","article-title":"Pharmacokinetics and tissue distribution of enavogliflozin in mice and rats","volume":"14","author":"Pang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2015.10.009","article-title":"Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye","volume":"145","author":"Chastain","year":"2016","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010134","article-title":"Topical drug delivery to the posterior segment of the eye","volume":"14","author":"L\u00f6scher","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2012.04.004","article-title":"Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease","volume":"31","author":"Kur","year":"2012","journal-title":"Prog. Retin Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2017.12.001","article-title":"Neural control of choroidal blood flow","volume":"64","author":"Reiner","year":"2018","journal-title":"Prog. Retin Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib57","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.10-6518","article-title":"Significance of outer blood-retina barrier breakdown in diabetes and ischemia","volume":"52","author":"Xu","year":"2011","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2025.118722_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2023.07.028","article-title":"Selective drug delivery to the retinal cells: Biological barriers and avenues","volume":"361","author":"Ramsay","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2025.118722_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090865","article-title":"In vitro metabolism of DWP16001, a novel sodium-glucose cotransporter 2 inhibitor, in human and animal hepatocytes","volume":"12","author":"Kim","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118722_bib61","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-016-0379-5","article-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review","volume":"33","author":"Kalra","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.biopha.2025.118722_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2885.2004.00600.x","article-title":"Plasma terminal half-life","author":"Toutain","year":"2004","journal-title":"J. Vet. Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.118722_bib63","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.me.36.020185.002225","article-title":"Elimination half-life of drugs: value and limitations","volume":"36","author":"Greenblatt","year":"1985","journal-title":"Annu Rev. Med"},{"key":"10.1016\/j.biopha.2025.118722_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin Eye Res"},{"key":"10.1016\/j.biopha.2025.118722_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2025.01.010","article-title":"An update on ocular effects of anti-diabetic medications","author":"Sadeghi","year":"2025","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118722_bib66","doi-asserted-by":"crossref","DOI":"10.1001\/archopht.1995.01100020037025","article-title":"Effects of ocular surface area and blink rate on tear dynamics","volume":"113","author":"Tsubota","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118722_bib67","doi-asserted-by":"crossref","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharm."},{"key":"10.1016\/j.biopha.2025.118722_bib68","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.6218-10.2011","article-title":"Characterizing the spontaneous blink generator: an animal model","volume":"31","author":"Kaminer","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118722_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/S0039-6257(00)00110-7","article-title":"Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach","volume":"44","author":"Doughty","year":"2000","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118722_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/S0042-6989(03)00005-1","article-title":"In vivo pachymetry in normal eyes of rats, mice and rabbits with the optical low coherence reflectometer","volume":"43","author":"Schulz","year":"2003","journal-title":"Vis. Res"},{"key":"10.1016\/j.biopha.2025.118722_bib71","first-page":"150","article-title":"Precise longitudinal monitoring of corneal change through in vivo confocal microscopy in a rat dry eye disease model","volume":"30","author":"Chen","year":"2024","journal-title":"Mol. Vis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:03:30Z","timestamp":1777014210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":71,"alternative-id":["S0753332225009163"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118722","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically-based pharmacokinetic modeling of enavogliflozin ophthalmic solution for starting dose selection in diabetic retinopathy treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118722"}}